

1 **Shank3 deficiency severely dampens calcium buffer capacity in**  
2 **dopaminergic neurons from the ventral tegmental area**

3 **Running Title:** Reduced calcium buffer capacity in Shank3<sup>-/-</sup> dopaminergic  
4 neurons

5 Lulu Lü<sup>†1,2</sup>, Yubo Lai<sup>†1</sup>, Runfeng Sun<sup>†1</sup>, Ruolin Liu<sup>§1</sup>, Junhui Lai<sup>1</sup>, Mengye Zhu<sup>3</sup>, Yunshen Chen<sup>1</sup>,  
6 Qinglian Liu<sup>4</sup>, Lei Zhou<sup>\*1</sup>

7 <sup>1</sup>Institute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen, Guangdong 518000,  
8 P.R.China;

9 <sup>2</sup>School of Basic Medical Sciences, Capital Medical University, Beijing 100054, P.R.China;

10 <sup>3</sup>Department of Pain Medicine, The First Affiliated Hospital of Nanchang University, Jiangxi Medical  
11 College, Nanchang University, Nanchang, Jiangxi 330006, P.R.China;

12 <sup>4</sup>Department of Physiology and Biophysics, School of Medicine, Virginia Commonwealth University,  
13 Richmond, VA 23298, USA.

14 <sup>†</sup>Contribute equally

15 \*Correspondence to: Lei Zhou: [zhoulei@szbl.ac.cn](mailto:zhoulei@szbl.ac.cn)

16

17 **Acknowledgments**

18 We acknowledge the discussion and technical support from other members of the lab. L. Zhou is  
19 supported by fundings from the National Natural Science Foundation of China (#32171150),  
20 Shenzhen Bay Laboratory (Startup Fund and Major Program of SZBL), Pearl River Talents  
21 Program of Guangdong Province, and Shenzhen Peacock Project. Q. Liu is supported by fundings  
22 from Virginia Commonwealth University (CTSA) and NIH (R01GM098592). The authors declare  
23 no competing interests.

24

25 **Lay Summary**

26 SHANK3 is a scaffolding protein highly enriched in the postsynaptic density (PSD) of excitatory  
27 synapses. Mutations and deletions of the *SHANK3* gene are the primary risk factor for Phelan-  
28 McDermid syndrome (PMS) and autism spectrum disorders (ASD). The links between the genetic  
29 alterations in the *SHANK3* gene and the abnormalities at cellular, network, and behavior levels  
30 have been unclear. This study uncovered abnormal calcium signaling and action potential firing in  
31 dopaminergic neurons. Calcium plays a central role in almost every aspect of neuronal physiology.  
32 A definitive link between defects in the SHANK3 protein, the calcium buffering system, and a  
33 psychiatric disorder is established for the first time.

34

35 **Abstract**

36 The intracellular calcium buffer system plays a critical role in shaping the spatiotemporal profile of  
37 calcium signaling. In contrast to calcium influx and clearance from the cytosol, our understanding  
38 of the calcium buffer system and its role in neuropsychiatric disorders is limited. Shank3 deficiency  
39 is a key risk factor for autism and other psychiatric disorders, and many important downstream  
40 mechanisms, relating to signaling pathways, cellular physiology and morphology, and neuronal  
41 circuitry, have been uncovered. Here we report prominent alterations in the calcium signaling profile  
42 of Shank3<sup>-/-</sup> dopaminergic (DA) neurons in the ventral tegmental area (VTA). Calcium transients  
43 from Shank3<sup>-/-</sup> DA neurons exhibit enhanced amplitudes and faster decay rates. Subsequent  
44 proteomic analysis of VTA brain tissue revealed that parvalbumin (PV) expression was significantly  
45 downregulated, which was subsequently confirmed by immunostaining results. As PV is an  
46 important component of the endogenous calcium buffer system, we employed the added-buffer  
47 approach together with 2-photon and ratiometric calcium and demonstrated a reduction in the  
48 endogenous calcium buffer capacity ( $K_E$ ) in Shank3<sup>-/-</sup> neurons. Therefore, the downregulation of  
49 PV protein and the associated decrease in calcium buffer capacity are key pathogenic factors  
50 resulting from Shank3 deficiency.

51

52 **Keywords:** Autism, Shank3, calcium buffer capacity, ventral tegmental area, dopaminergic neuron,  
53 parvalbumin.

54

55

56

## 57 Introduction

58

59 Calcium serves as a central second messenger in both excitable cells, such as neurons and  
60 muscles, and non-excitabile cells (Clapham, 2007; Eisner et al., 2023). The dynamic profile of free  
61 calcium ion concentration within the cytosol encodes vital information for numerous physiological  
62 processes (Leybaert and Sanderson, 2012; Evans and Blackwell, 2015; Jedrzejewska-Szmek et  
63 al., 2023). Much focus has been placed on the influx of calcium ions through cell surface channels  
64 and receptors, the release of calcium from internal stores into the cytosol, and the clearance of  
65 excess calcium from the cytosol (Enomoto et al., 2017). Malfunctions in any of these steps have  
66 serious consequences and may contribute to the development of various neuropsychiatric diseases  
67 (Nanou and Catterall, 2018; Pchitskaya et al., 2018). However, one critical aspect of cytosolic  
68 calcium signaling is often overlooked: approximately 99% of cytosolic calcium is bound to calcium-  
69 binding proteins (Brinley, 1978; Matthews and Dietrich, 2015; Schwaller, 2020). Therefore,  
70 components of the calcium buffer system exert a profound influence on the spatiotemporal profile  
71 of calcium signaling: they serve as essential protective absorbents against toxic levels of calcium,  
72 but they also directly release calcium when free calcium concentrations are low (Fakler and  
73 Adelman, 2008). Notably, low expression of PV, a 12 kDa calcium-binding protein, has been  
74 reported in neurodegenerative diseases and autism spectrum disorders (ASD) (Jung et al., 2019;  
75 Filice et al., 2020; Janickova et al., 2020; Contractor et al., 2021; Ruden et al., 2021). During the  
76 progress of both acute and long-term neuropsychiatric disorders, neurons of intrinsically high PV  
77 expression often exhibit increased metabolic and translational activity, making them more  
78 vulnerable to pathological damage (Hu et al., 2014; Ruden et al., 2021; Tang et al., 2021; Kumar  
79 et al., 2024). However, a direct connection between abnormalities in calcium buffering capacity and  
80 nervous system disorders has yet to be established.

81

82 The *SHANK3* gene encodes an important scaffolding protein highly enriched in the postsynaptic  
83 density (PSD) of glutamatergic synapses (Durand et al., 2007; Leblond et al., 2014). The full-length  
84 Shank3 protein contains highly conserved domains that mediate protein-protein interactions,  
85 including an Ankyrin repeat domain, an SH3 domain, and a PDZ domain, followed by a proline-rich  
86 region and a SAM domain. Multiple intragenic promoters within the *SHANK3* gene, along with  
87 alternative exon splicing, resulting in a complex cohort of SHANK3 isoforms (Wang et al., 2014).  
88 Beyond PSD, Shank3 is also expressed in the soma, axons, presynaptic terminals, and even the  
89 nucleus, but the function of Shank3 in these areas remains to be clarified (Wang et al., 2014;  
90 Halbedl et al., 2016b; Han et al., 2016).

91

92 Mutations in the *SHANK3* gene have been linked to several brain disorders, including Phelan-  
93 McDermid syndrome (PMS), ASD, schizophrenia, mania, and dementia. Despite these  
94 associations, many gaps exist in understanding how genetic defects translate into behavioral  
95 phenotypes in *SHANK3*-related pathology. To address this, dozens of Shank3 knockout mouse  
96 models of various designs have been developed, and to varying extents, they have recapitulated  
97 the neurological symptoms observed in human patients (Peca et al., 2011; Bariselli et al., 2016;  
98 Wang et al., 2016; Drapeau et al., 2018; Delling and Boeckers, 2021). At the cellular level, Shank3  
99 deficiency causes abnormalities in the morphology of neuronal structures, the surface expression  
100 and localization of various receptors and ion channels, synaptic transmission and plasticity, and  
101 neurophysiological activities at the cellular and circuit levels. Among the plethora of ion channels  
102 expressed in neurons, the downregulation of HCN channel expression and function of HCN  
103 channels is considered a primary consequence of Shank3 deficiency (Yi et al., 2016; Zhu et al.,  
104 2018). This downregulation of HCN channels directly causes abnormal neuronal excitability,  
105 including aberrant action potential firing, negatively shifted resting membrane potential,  
106 and increased input resistance (Santoro and Shah, 2020; Combe and Gasparini, 2021).

107

108 The HCN channelopathy resulting from Shank3 deficiency has been studied in two types of  
109 excitatory neurons: the pyramidal neurons in the hippocampus and the thalamocortical neurons in  
110 the thalamus (Yi et al., 2016; Zhu et al., 2018). Here we characterized the DA neurons in the VTA.  
111 Most DA neurons in the brain are densely distributed in the VTA, which harbors neuronal circuits  
112 important for the reward system (Schultz et al., 1997; Cohen et al., 2012; Morales and Margolis,  
113 2017). In *Shank3*<sup>-/-</sup> DA neurons, we identified abnormalities in action potential firing and calcium  
114 signaling profile and established the link between Shank3 deficiency and downregulation of  
115 cytosolic calcium buffering capacity.

116

117

## 118 **Materials and Methods**

119

### 120 *Ethical approval*

121 All animal experiments were approved by the IACUC Committee of Shenzhen Bay Laboratory.  
122 C57BL/6J mice were used in the current study. The number of animals and as well as procedures  
123 involving pain were minimized in compliance with regulations. Animals were subjected to regular  
124 veterinary care on a routine basis. The Center for Research Animal Resources was available 24  
125 hours for any case in which veterinary care or consultation was required. Mice were housed in a  
126 standard 12-hour light/dark cycle, with free access to food and water. The Shank3 knockout mice  
127 were purchased from The Jackson Laboratory (B6.Cg-*Shank3*<sup>tm2.1Bux</sup>/J, Stock No: 017688; jax.org).

128

129 *Acute brain slice preparation and whole-cell patch-clamp recording*

130 Coronal brain slices were prepared from mice 3-6 weeks old of either sex. In brief, mice were deeply  
131 anesthetized by intraperitoneal injection of 1.25% Tribromoethanol (avertin; 0.2 mL/10 g body  
132 weight) and then transcidentally perfused through the ascending aorta with preoxygenated (95% O<sub>2</sub>  
133 and 5% CO<sub>2</sub>) and ice-cold sucrose-based artificial cerebrospinal fluid (sucrose-ACSF). Brain slices  
134 of 300 μm thickness were prepared using a vibratome (VT1200S Leica) at 4°C. Slices were  
135 incubated first at 34°C for 30 min in standard ACSF and subsequently kept at room temperature  
136 for at least 1 hour prior to recording.

137

138 Brain slices were perfused continuously in the recording chamber with pre-warmed (34°C)  
139 carbonated standard ACSF at a rate of 2-3 ml/min. Visually identified healthy neurons were  
140 recorded with glass pipettes (4-6 MΩ) filled with the internal solution. Voltage and current signals  
141 recorded from neuron soma were amplified by MultiClamp 700B (Molecular Devices), digitized by  
142 an A/D converter (NI USB-6341, National Instruments) and acquired by WinWCP (Dr. John  
143 Dempster, University of Strathclyde). All electrophysiological data is collected at a sampling  
144 frequency of 20 kHz, with the amplifier filter set at 10 kHz. Resting membrane potential and input  
145 resistance data are recorded immediately after membrane rupture. Action potential and other  
146 signals were recorded from neurons that have remained stable for at least 5 minutes after  
147 membrane rupture. Data were offline converted to Axon file format and analyzed by Clampfit  
148 (Molecular Devices). Neurons with an RMP more negative than -50 mV and the peak of action  
149 potential (AP) passing 0 mV were selected for recording. Input resistance (R<sub>in</sub>) was measured at  
150 RMP based on the change in membrane potential in response to a 10 pA current injection (500  
151 msec). APs were elicited with depolarizing current pulses according to the description in the text.

152

153 *Two-Photon Calcium Imaging*

154 An Olympus two-photon microscope (FVMPE-RS) with custom IR-DIC was used for calcium  
155 imaging in neuron soma and dendrites. A femtosecond pulsed laser (Spectra-Physics) at 810 nm  
156 was used for calcium dye and AF594 excitation. Fluorescence signals were collected by a 25X  
157 water immersion objective lens for multi-photon recording (ND 1.05, WD 2.0 mm, 400-1600 nm  
158 applicable, Olympus) and recorded through the green channel (495-540 nm emission filter) and the  
159 red channel (575-645 nm filter) by two GaAsP PMTs (RNDD3G; RNDD4G). The TTL signal  
160 generated by the WinWCP program was used to trigger the recording of time-lapse images at the  
161 frequency of 25 frames per second. To minimize photobleaching, the laser power was typically set  
162 in the range of 3.5 - 5%. To approach optimal intensity of each frame, Galvan instead of Resonant  
163 scanner was used and the exposure time was in the range between 10 and 20 μs/pixel. The size

164 of ROI was adjusted so that the frame rate can reach 25 Hz. The fluorescence intensity of each  
165 ROI was monitored on-line during each experiment and analyzed off-line using Clampfit.  
166 Background fluorescence was subtracted by manual selection of an area away from the electrode,  
167 soma, and dendrites. Optical and electrical recordings were carried out simultaneously. Burst firing  
168 of TRN neurons was triggered by 3 or 4 current injections (500 pA / 10 msec duration / 1 second  
169 interval) at the RMP of -70 mV. No averaging and filtering were applied to the fluorescence signal  
170 during data analysis.

171

172

### 173 *Ratiometric calcium imaging*

174 Fura-8, a high-affinity ratiometric calcium indicator, was alternatively excited by two LED light  
175 sources, 365 nm and 410 nm. Fluorescence signals were collected by a 40X water immersion lens  
176 (CFI Apo NIR 40X W, Nikon), passed through the filter cube, and detected by a back-illuminated  
177 sCMOS camera (Dhyana 400BSI by Tucsen). The exposure time and frame rate were set at 20  
178 msec and 40 Hz, respectively. A total of 390 images were recorded at 40 Hz (195 data points at 20  
179 Hz) for each episode. ImageJ and Clampfit were used for data analysis. TTL signals generated by  
180 the WinWCP program were used to synchronize the electrophysiology amplifier (AM2400, A-M  
181 Systems), the LED light sources, and the sCMOS camera.

182

183 The procedure for calculating the free calcium concentration was based on published studies (Zhou  
184 and Neher, 1993; Maravall et al., 2000; Delvendahl et al., 2015; Helmchen and Tank, 2015). The  
185 endogenous calcium buffer power was estimated by the “added buffer” approach where exogenous  
186 calcium buffers at different capacities compete with endogenous buffers. The analysis involves the  
187 calculation of fluorescence intensity ( $F_i$ ) and the effective binding constant ( $K_{eff}$ ), as outlined in  
188 equations (1) and (2) as described below:

189

### 190 **Step 1: calculation of intracellular fluorescence intensity $F_i$**

191  $F_i$  can be calculated using the following formula:

$$192 \quad F_i = F_1 + \alpha F_2 \quad (1)$$

193 , where  $F_1$  and  $F_2$  represent the fluorescence intensity measured at 365 nm and 410 nm,  
194 respectively, and  $\alpha$  represents the isocoefficient so that  $F_i$  is independent of calcium concentration.  
195 The background fluorescence intensity was subtracted from all measurements.  $F_i$  serves as an  
196 indicator independent of calcium concentration and can reflect the concentration of Fura-8 inside  
197 the neuron. As the whole-cell patch-clamp recording progresses after the rupture of the membrane  
198 seal, the  $F_i$  value gradually increases.

### 199 **Step 2: calculation of the effective binding constant $K_{eff}$ of Fura-8**

200 
$$K_{eff} = K_D \frac{R_{max} + \alpha}{R_{min} + \alpha} \quad (2)$$

201 , where  $K_D$  represents the dissociation constant of Fura-8 (260 nM),  $R_{max}$  and  $R_{min}$  are the  
202 maximum and minimal ratios of intensity measured using an electrode solution containing 10 mM  
203  $CaCl_2$  and 10 mM EGTA, respectively.

204 **Step 3: calculation of intracellular free calcium ion concentration**

205 
$$[Ca^{2+}] = K_{eff} \frac{R - R_{min}}{R_{max} - R} \quad (3)$$

206 , where  $R$  represents the ratio of fluorescence intensities excited by 365 nm and 410 nm light. The  
207 resting calcium ion concentration  $[Ca^{2+}]_{rest}$  and the peak calcium ion concentration  $[Ca^{2+}]_{peak}$  after  
208 induced AP firing can be obtained from eq. 3.

209 **Step 4: calculation of calcium buffer capacity  $K_B$**

210 After the rupture of the membrane seal, the concentration of Fura-8 - as well as the corresponding  
211 calcium buffer capacity  $K_B$  - gradually increases in the cytosol.  $[B]_t$  represents the concentration of  
212 the calcium dye inside the neuron and can be calculated by the following equation:

213 
$$[B]_t = [B]_p \cdot F_i / F_{i\infty} \quad (4)$$

214 , where  $[B]_p$  is the total concentration of Fura-8 in the electrode solution (50  $\mu$ M),  $F_i$  represents the  
215  $F_i$  value at a given time and can be calculated from formula (1), and  $F_{i\infty}$  represents the  $F_i$  value  
216 when Fura-8 reaches equilibrium inside the neuron (typically after 20 minutes), also calculated from  
217 formula (1).

218

219 The  $K_B$  can be calculated by:

220 
$$K_B = \frac{[B] \cdot K_D}{([Ca^{2+}]_{rest} + K_D)([Ca^{2+}]_{peak} + K_D)} \quad (5)$$

221 , where  $K_D$  is the dissociation constant of Fura-8 (260 nM);  $[Ca^{2+}]_{rest}$  and  $[Ca^{2+}]_{peak}$  can be obtained  
222 from formula (3).

223 **Step 5: calculation of decay time constant of calcium transients**

224 After rupturing the cell membrane, the exogenous calcium buffer power  $K_B$  increases as Fura-8  
225 gradually enters the neuron. Increased calcium buffer power tends to decrease the amplitude of  
226 the calcium transients and increase the time constant for the decay phase. The decay time constant  
227  $\tau$  of the calcium transients can be obtained using Clamfit software. The relationship between  $K_B$   
228 and  $\tau$  at different time points can be fitted into a linear equation:

229 
$$\tau = \frac{1 + K_B + K_E}{\gamma} \quad (6)$$

230 , where  $\tau$  is obtained from Clamfit software,  $K_B$  is calculated using formula (5), and the negative x-  
231 axis intercept provides an estimate of the endogenous buffer capacity  $K_E$ . Following this procedure,

232 we can determine the endogenous calcium buffer capacity of neurons from WT and SHANK3-/-  
233 mice.

234 *Solutions used (all in mM):*

235 Heart perfusion and brain slice preparation solution: Sucrose, 220; KCl, 2.5; NaH<sub>2</sub>PO<sub>4</sub>, 1.25;  
236 MgSO<sub>4</sub>, 6; CaCl<sub>2</sub>, 0.5; NaHCO<sub>3</sub>, 25; Glucose, 20; ascorbic acid, 0.4; Na Pyruvate, 2.

237 Brain slice incubation and recording solution: NaCl, 125; KCl, 2.5; NaH<sub>2</sub>PO<sub>4</sub>, 1.25; MgSO<sub>4</sub>, 2; CaCl<sub>2</sub>,  
238 2; NaHCO<sub>3</sub>, 25; Glucose, 20; Ascorbic acid, 0.4; Na Pyruvate, 2.

239 Standard electrode solution: KGluconate, 130; KCl, 5; MgSO<sub>4</sub>, 2; Creatine Phosphate, 5; ATP, 1;  
240 GTP, 0.3; HEPES, 10 ; EGTA 0.5.

241 Electrode solution for calcium imaging: KGluconate, 130; KCl, 5; MgSO<sub>4</sub>, 2; Creatine Phosphate,  
242 5; ATP, 1; GTP, 0.3; HEPES, 10.

243 *Reagents used:*

244 For two-photon calcium imaging, two calcium indicators were used: Fluo-5F (pentapotassium salt)  
245 and Fluo-4 (pentapotassium salt). To trace neuronal soma and dendrites, a red fluorescent dye  
246 Alexa Fluor™ 594 (commonly abbreviated as AF 594) was used.

247 DHPG, an agonist of metabotropic glutamate receptors; Caffeine, an agonist of ryanodine receptors  
248 (RyRs); Ryanodine, an antagonist of RyRs; Isradipine, an antagonist of L-type voltage-gated  
249 calcium channels.

250

### 251 **Immunofluorescence Staining**

252 Mice under anesthesia were transcardially perfused with approximately 20 ml of ice-cold PBS  
253 solution, followed by 20 ml of pre-cooled 4% paraformaldehyde. Then the brain tissue was  
254 dissected out and immersed in 4% paraformaldehyde for overnight fixing, followed by soaking with  
255 30% sucrose for cryoprotection and then frozen in OCT medium.

256

257 Brain slices of 25 μm were prepared using a Leica cryostat and then washed in 0.1% PBST for 3  
258 times and 0.3% PBST for 20 minutes. After blocking with PBST and 10% goat serum for 1 hour,  
259 brain slices were incubated with primary antibodies (chicken anti-Tyrosine Hydroxylase (TH)  
260 antibody for labeling dopamine neurons and rabbit anti-PV antibody for PV protein labeling, both  
261 diluted 1:1000) at 4°C overnight. After rinsing three times, brain slices were incubated with  
262 secondary antibodies in the dark (594-goat anti-chicken, ab150176, Abcam, 1:1000; 488-goat anti-  
263 rabbit, ab150077, Abcam, 1:1000) at room temperature for 1 hour. After extensive rinsing, brain  
264 slices were mounted with sealing agent DAPI-Aqueous (ab104139, Abcam). Parameters of the  
265 confocal microscope, especially the laser power and detector gain, were pre-adjusted to minimize  
266 photobleaching. The same set of parameters were used in the data collection for parallelly  
267 processed WT and Shank3-/- mutant samples. After raw image to TIFF format (16 bit), ImageJ was

268 used for data analysis. For each brain slice, the VTA region was manually selected (Freehand  
269 selections) and cell bodies were registered with TH signal (red channel) as the guidance. The size  
270 parameter was set as 0.05-3 inch<sup>2</sup> (Analyze Particles). Then the ROI outputs were used to measure  
271 the PV signal (green channel) of the selected cell bodies. For each brain slice, we obtain the total  
272 number of TH+ neurons and the average PV signal intensity. Final statistics were based on results  
273 of all brain slices used in data analysis (**Fig. S3A-B**). To compare PV expressions between WT  
274 and Shank3<sup>+/-</sup> samples, we first converted the raw TIFF image (whole image selection) to an Excel  
275 file containing the X-Y coordinates and intensity of each pixel. With TH signal intensity as guidance  
276 (red channel, >50 a.u.), positive pixels were pooled together and their green channel intensities,  
277 corresponding to PV expression, were used in histogram analysis (**Fig. S3C-E**). Images from the  
278 mouse brain atlas, including the *in-situ* hybridization data of PV, were shown for reference purposes  
279 (**Fig. S3F**).

280

## 281 **Proteomics Analysis via Mass Spectrometry**

### 282 *Mouse Brain Tissue Collection*

283 A total of 9 WT mice and 9 Shank3<sup>-/-</sup> mice, each aged between 3-6 weeks and born from the same  
284 litter, were used in the experiments. The mice under anesthesia were transcardially perfused with  
285 pre-chilled PBS solution. The brain tissue was quickly trimmed and mounted on a sample holder  
286 for slicing. Coronal slices were prepared in slushy PBS using VT1200S with the following  
287 parameters: speed 0.06 mm/s, amplitude 0.85  $\mu$ m, and thickness 400  $\mu$ m. The VTA region was  
288 carefully dissected from the slices under a stereo-dissection microscope and saved in Eppendorf  
289 tubes.

290

### 291 *Total Protein Extraction*

292 The brain tissue was first rinsed in pre-chilled PBS and then mixed with pre-chilled membrane and  
293 cytoplasmic protein extraction buffer: Buffer A (C510005, Sangon Biotech) supplemented with 1  $\mu$ l  
294 DTT, 10  $\mu$ l PMSF, 1  $\mu$ l protease inhibitor, and 5  $\mu$ l phosphatase inhibitor. Stainless steel beads (3  
295 mm) were added into each EP tube for tissue homogenization, with a tissue grinder of the setting  
296 of 60 HZ for 60 seconds, followed by a 15-second pause, for a total of 3 cycles at -10°C. Then the  
297 homogenized tissue was centrifuged at 4°C, 3000 rpm for 3 minutes. Next, the tissue was further  
298 homogenized by an ultrasonic cell disruptor (KZ-5F-3D, Servicebio Inc), with the protocol of 30  
299 seconds on, 60 seconds off, for a total of 5 repeats at 25% power. The homogenized solution was  
300 centrifuged at 4°C, 4100 rpm for 10 minutes. The supernatant was collected and subjected to a  
301 second centrifugation step at 4°C, 13000 rpm for 90 minutes. The supernatant, corresponding  
302 mostly to the cytoplasmic soluble fraction, was collected and stored on ice. The pellet was then  
303 mixed with pre-chilled Buffer B (C510005, Sangon Biotech; 1 ml supplemented with 1  $\mu$ l DTT, 10

304  $\mu$ l PMSF, 1  $\mu$ l protease inhibitor, and 5  $\mu$ l phosphatase inhibitor), followed by extensive vortex and  
305 centrifugation at 4°C, 13000 rpm for 10 minutes. The supernatant, corresponding mostly to the  
306 membrane fraction, was transferred to a pre-chilled clean microcentrifuge tube. This is the  
307 membrane protein. The cytoplasmic and membrane proteins were mixed and stored at -80°C or  
308 proceeded to the protein precipitation step.

309

### 310 *Protein Precipitation*

311 To precipitate proteins, 250  $\mu$ l of a methanol/chloroform solution (4:1 ratio) was added to 200  $\mu$ l of  
312 the samples and incubated at -20°C for 2.5 hours. The precipitated proteins were pelleted by  
313 centrifugation at 17,000 xg for 10 min at 4°C. The protein pellets were washed three times with 1  
314 ml methanol (pre-chilled to -20°C) to remove chloroform and subsequently dried. Each sample was  
315 resuspended and dissolved in 100  $\mu$ l of 50 mM ammonium bicarbonate solution using sonication.

316

### 317 *Mass Spectrometry Analysis*

318 After protein concentration determination using the bicinchoninic acid (BCA) assay, each sample  
319 was adjusted to the same concentration (> 1  $\mu$ g/ $\mu$ l) using 50 mM ammonium bicarbonate. Urea  
320 was added to each sample to a final concentration of 2-4 M to fully solubilize the proteins. To reduce  
321 disulfide bonds, TCEP was added to a final concentration of 10 mM, and the samples were  
322 incubated at 37°C for 1 hour. Iodoacetamide was then added to a final concentration of 20 mM to  
323 modify cysteine residues and prevent disulfide bond formation. After diluting the samples 3 times  
324 with 50 mM ammonium bicarbonate, trypsin was added to a final concentration of 4.8 ng/ $\mu$ l, and  
325 the samples were incubated at 37°C for 16-18 hours to allow complete digestion by trypsin. Typical  
326 protein concentration was in the range of 0.1-5  $\mu$ g/ $\mu$ l. Thermo Hypersep C18 columns were used  
327 for desalting. After drying to remove acetonitrile from the C18 column elution, the final samples  
328 were dissolved in 0.1% formic acid. The concentration of each sample was adjusted to 250 ng/ $\mu$ l.  
329 Samples were then subjected to mass spectrometry analysis using an Exploris 480 Hybrid  
330 Quadrupole-Orbitrap Mass Spectrometer.

331

### 332 **Expression and Purification of mouse parvalbumin (PV)**

333 The open-reading frame of mouse PV was amplified and cloned into the pSMT3 vector (a generous  
334 gift from Dr. Christopher Lima, MSK Cancer Center). After the DNA sequence was confirmed by  
335 sequencing, the resulting pSMT3-PV plasmid was transformed into the *E. coli* BL21(DE3) strain for  
336 expression. Expression was induced at 30 °C for 8 hours in LB Miller medium by adding IPTG to a  
337 final concentration of 1 mM. The mouse PV was expressed as a Smt3 fusion protein with a His6  
338 tag at the N-terminus. A HisTrap column (Cytiva) was used for the first step of purification, with  
339 buffers containing 25 mM Hepes-NaOH, pH 7.5, 300 mM NaCl, 10% glycerol, and 1 mM TCEP.

340 After incubating with the Ulp1 protease overnight, the Smt3 tag was cleaved off. A second HisTrap  
341 was applied to remove the Smt3 tag. The resulting protein was > 95% pure and concentrated to >  
342 10 mg/ml. After aliquoting to 50  $\mu$ l per tube, the purified PV protein was flash-frozen and stored in  
343 a -80 °C freezer.

344

### 345 **Statistics**

346 All statistical tests were performed using the program of OriginPro. Data are presented as mean  $\pm$   
347 SEM. Statistical significance was assessed with unpaired student t test.  $P < 0.05$  was considered  
348 statistically significant, and significance is indicated as follows: \*\*\*,  $P < 0.001$ ; \*\*,  $P < 0.01$ ; \*,  $P <$   
349  $0.05$ . P-value is provided in figure legends.

350

351

### 352 **Results**

353

354 *Abnormal neuronal excitability and faster somatic calcium signal clearance in Shank3<sup>-/-</sup> VTA DA*  
355 *neurons*

356 We started with electrophysiological characterization of VTA DA neurons from WT and Shank3<sup>-/-</sup>  
357 mice (**Fig. 1A, 1B**). To evoke action potential (AP) firing, a series of current injections, at the interval  
358 of +50 pA, were applied to the neuron. In Shank3<sup>-/-</sup> DA neurons, we observed significant decreases  
359 in the number, half-width, and half-amplitude of AP (**Fig. 1C-1E**). The resting membrane potential  
360 (RMP) of the Shank3<sup>-/-</sup> neuron was slightly negative than that of WT, whereas the input resistance  
361 was comparable (**Fig. 1F**).

362

363 Calcium plays a key role in bridging neuronal excitability to various physiological processes and is  
364 the most important second messenger in neurons. Next, we examined the profile of somatic calcium  
365 signaling using 2-photon calcium imaging. Calcium dyes (200  $\mu$ M Fluo-4) were loaded into the  
366 neuron through whole-cell recording pipettes, with four short current injection pulses at time  
367 intervals to trigger AP firing (**Fig. 2A-2B**). Two calcium dyes with different  $K_D$  values were used in  
368 the experiments: Fluo-4, a high-affinity dye with a  $K_D$  of approximately 345 nM, and Fluo-5F, a low-  
369 affinity dye with a  $K_D$  of approximately 2.3  $\mu$ M. In Shank3<sup>-/-</sup> DA neurons, the amplitudes of the  
370 calcium transients were consistently higher whereas the decay proceeded much faster compared  
371 to WT neurons (**Fig. 2C-2F**).

372

373

374 *Altered dendritic calcium signaling in Shank3<sup>-/-</sup> VTA DA neurons*

375 Next we examined the profile of dendritic calcium signaling using two-photon calcium imaging (**Fig.**  
376 **3A**). We started from Fluo-4, a high-affinity calcium dye with a  $K_D \sim 345$  nM. After membrane break-  
377 in, we waited  $\sim 20$  minutes before collecting images of dendritic fluorescence signal. We chose  
378 three spots along the same dendritic trunk, at distances of 50, 100, or 150  $\mu\text{m}$  from the soma, and  
379 recorded the calcium transients in response to the same set of somatic current injections as used  
380 above. Analysis of the time constant and the amplitude of the calcium transients revealed  
381 interesting changes consistent with those observed at the soma: faster decay and increased  
382 amplitude of dendritic calcium transients in Shank3<sup>-/-</sup> neurons (**Fig. 3B-3C**). In addition, we tested  
383 Fluo-5F, a low-affinity calcium dye with a  $K_D$  of  $\sim 2.3$   $\mu\text{M}$  (**Fig. 3D**). From the soma to three spots  
384 along the dendritic trunk, the calcium transients of the Shank3<sup>-/-</sup> DA neuron showed a faster decay  
385 (**Fig. 3E-3F**).

386

387 *Reduced PV expression in Shank3<sup>-/-</sup> VTA neurons revealed by mass spectrometry and*  
388 *immunostaining*

389 To explore the molecular basis of the faster calcium clearance in Shank3<sup>-/-</sup> neurons, we started  
390 with a pharmacological approach by perturbing the relevant calcium influx and clearance pathways.  
391 However, the results could not explain the faster decay of calcium transients observed in Shank3<sup>-/-</sup>  
392 neurons (**Fig. S1**). We then utilized a systematic proteomics approach to evaluate the proteins  
393 that show abnormal expression upon Shank3 deficiency. To improve the specificity for the VTA  
394 region, we dissected the brain tissue in the VTA region of WT and Shank3<sup>-/-</sup> mice and subjected  
395 the protein extraction to mass spectrometry analysis (**Fig. 4A**). Among the 4882 identified proteins,  
396 132 differentially expressed proteins were identified ( $P < 0.05$ ), of which 86 were upregulated and  
397 46 were downregulated (**Fig. 4B**). We then subjected the mass-spec results to clustering, gene  
398 ontology (GO), and KEGG pathway analysis (**Fig. 4C-D; S2**). Among the 132 differentially  
399 expressed proteins, 29 proteins were found to be closely related to cytoskeletal protein and cell  
400 metabolism and development by cluster analysis. Interestingly, GO analysis revealed that the  
401 proteins affected by Shank3 deficiency function in regulating the cytoskeleton and associated  
402 channels and receptors on the membrane. These structural proteins may contribute to biological  
403 processes such as epidermal development and differentiation. The KEGG analysis identified 15  
404 pathways, including metabolic pathways, reactive oxygen species, and neuropsychiatric diseases  
405 such as Huntington's disease.

406

407 As revealed by mass-spec analysis, PV is at the top of the list of proteins showing reduced  
408 expression in the Shank3<sup>-/-</sup> VTA region. PV is an important calcium-binding protein and critically  
409 regulates the spatial and dynamic profile of intracellular calcium. Reduced levels of PV protein  
410 could decrease the capacity of calcium buffer, which in theory leads to an increase in calcium

411 transient amplitude and an acceleration of the decay phase (Eisner et al., 2023). To confirm the  
412 mass spectrometry results, we performed immunostaining of PV proteins from fixed brain slices  
413 (**Fig. 4E**). Brain slices were collected from paired littermates and processed in parallel during the  
414 staining and imaging steps. Tyrosine hydroxylase (TH), a marker for DA neurons, was stained and  
415 shown in red, while PV was stained in green. The composite images of the soma of VTA DA  
416 neurons showed a dramatic difference between the WT and Shank3<sup>-/-</sup> samples, with the WT  
417 sample showing a yellowish color, whereas the Shank3<sup>-/-</sup> sample remained red, indicating reduced  
418 expression of PV (**Fig. 4F-4H; S3A-S3B**). Interestingly, PV expression in Shank3<sup>+/-</sup> heterozygote  
419 mice also showed significant decreases, as revealed by a pixel-based quantitative intensity  
420 analysis guided by TH signals (**Fig. S3C-E**). Notably, the expression level of PV in DA neurons is  
421 clearly lower than the “PV+” neuron from nearby regions, including substantia nigra and midbrain  
422 reticular nucleus, which is consistent with the in-situ hybridization data (**Fig. S3F**). In addition,  
423 Shank3<sup>-/-</sup> PV+ neurons in the cortex exhibited a significant decrease in PV expression (**Fig. S4**).  
424

#### 425 *Decreased calcium buffer capacity in Shank3<sup>-/-</sup> VTA DA neurons*

426 PV is a critical component of the endogenous calcium buffering system. We were intrigued by the  
427 greatly reduced expression of PV in Shank3<sup>-/-</sup> neurons as shown above. We set out to quantify the  
428 capacity of the calcium buffering system using the “added buffer” approach. The cytosolic calcium  
429 buffer capacity critically determines the amplitude and the decay time constant of calcium  
430 transients. As an “added perturbation” to the endogenous calcium buffer system, calcium dyes  
431 loaded into the neuron tend to decrease the amplitude and increase the decay time constant of  
432 calcium transients, respectively, which helps the extrapolation of endogenous calcium buffer  
433 capacity. We started with 2-photon calcium imaging based on a single wavelength dye, and to  
434 improve the accuracy of the measurements, corroborated the results with radiometric calcium  
435 measurements.

436

437 We started from Fluo-4 and the 2-photon calcium imaging setup to quantify the endogenous  $K_E$   
438 (**Fig. 5A**). A series of short current injections (2 nA, 2 msec, 2 Hz), was used to evoke AP at fixed  
439 time points. The corresponding calcium transients were recorded within 30 minutes after membrane  
440 break-in (**Fig. 5B-5C**). As indicated by the fluorescence of AF594, the concentration of calcium dye  
441 steadily increased and eventually reached equilibrium within 20-30 minutes (**Fig. 5D**).  
442 Corresponding to the time-dependent increase in the buffer capacity of Fluo-4 ( $K_B$ ), a significant  
443 slowdown in calcium transient decay was observed (**Figs. 5E**). Linear regression fitted to the  
444 dataset of  $\tau$ - $K_B$  revealed the relative value of the endogenous calcium buffer,  $K_E$  (**Fig. 5F**). As  
445 expected, the  $K_E$  value of Shank3<sup>-/-</sup> DA neurons is smaller than that of the WT neurons by  
446 approximately 23 (**Fig. 5G**).

447

448 Next, we used Fura-8, an improved version of the widely used ratiometric calcium dye Fura-2, on  
449 a home-built imaging system based on a back-illuminated sCMOS camera (**Fig. 6A**). Fura-8 was  
450 alternately excited by 365 and 410 nm light, with the corresponding fluorescence intensity showing  
451 opposite changes during a calcium transient (**Fig. 6B-6D**). After the membrane break-in, the  
452 calcium dye in the recording pipette began to diffuse into the neuron, eventually reaching  
453 equilibrium in approximately 20 minutes. Compared to the calcium transients recorded from WT  
454 DA neurons, the Shank3<sup>-/-</sup> calcium signal showed increased amplitude and faster decay, indicating  
455 the reduced calcium buffer capacity (**Fig. 6E**). To quantify the impacts on endogenous calcium  
456 buffer capacity, we used the “added buffer” approach by tracking changes in calcium transients for  
457 12 minutes and subjecting collective  $\tau$  measurements to linear regression analysis (**Figs. 6F-6G**).  
458 Averaged results based on measurements from a total of 14 cells revealed that the  $K_E$  value of  
459 Shank3<sup>-/-</sup> is reduced by approximately 61 compared to that of WT (**Fig. 6H**).

460

461

## 462 Discussion

463

464 SHANK3 deficiency is a highly penetrant monogenic risk factor for ASD and several other  
465 neuropsychiatric disorders. The connections between genetic defects in the *SHANK3* gene and the  
466 resulting behavior phenotypes remain unclear. Although Shank3 is known to be a canonical  
467 synaptic protein, its role in other neuronal structures, such as the soma and dendrites, is  
468 underappreciated (Wang et al., 2014; Halbedel et al., 2016a). Previous research suggested that the  
469 primary consequence of Shank3 deficiency is the effect on neuronal excitability, mediated by HCN  
470 channelopathy. In the current study of Shank3<sup>-/-</sup> VTA dopaminergic neurons, we discovered  
471 changes in AP firing and an intriguingly fast decay of calcium transients. Significantly reduced PV  
472 expression, and consequently reduced calcium buffer capacity, were responsible for the abnormal  
473 calcium signaling. Thus, this study extended our understanding of the downstream events of  
474 Shank3 deficiency and highlighted the critical role of calcium buffer capacity in related  
475 neuropsychiatric disorders.

476

477 The majority of DA neurons in the brain are concentrated in the VTA and surrounding regions. It  
478 has been proposed that the hypoactivity in DA neurons directly contributes to the maturation of the  
479 corresponding circuits during development, thereby underpinning the behavior phenotypes  
480 observed in autistic patients (Bariselli et al., 2016; Bariselli et al., 2018). Our electrophysiological  
481 characterization of Shank3<sup>-/-</sup> VTA DA neurons revealed reduced AP firing, shorter AP half-widths,  
482 and negatively shifted RMP.

483

484 In addition, the calcium transients in Shank3<sup>-/-</sup> VTA DA neurons exhibit an abnormally fast decay.  
485 The spatiotemporal profile of calcium signaling is strongly influenced by the intracellular calcium  
486 buffering system. Reduced buffer capacity tends to increase the immediate peak of calcium  
487 transients, as the sudden influx of calcium ions quickly overwhelms the intracellular buffers. This  
488 transient increase in free calcium could enhance the opening of nearby channels such as the BK  
489 potassium channel, potentially contributing to abnormalities in AP shape and firing in Shank3<sup>-/-</sup>  
490 neurons (Hou et al., 2016). During the decay phase, which lasts tens to hundreds of milliseconds,  
491 reduced calcium buffer capacity allows free calcium ions to have more opportunities to interact with  
492 the clearance system, resulting in faster clearance of intracellular free calcium. Additionally,  
493 reduced PV expression limits its capacity as an important source of calcium during the decay phase  
494 (Collin et al., 2005; Franconville et al., 2011). In Shank3<sup>-/-</sup> neurons, this faster decay may limit the  
495 spatial scale of cytosolic calcium increases, thereby dampening longer-range events such as SK  
496 channel opening or increases in calcium concentration in subcellular structures or organelles (Ma  
497 et al., 2023). To further validate the relationship between calcium buffer capacity and the profile of  
498 calcium transients, we compensated for the reduced PV expression in Shank3<sup>-/-</sup> DA neurons by  
499 adding additional EGTA (350  $\mu$ M; **Fig. S5**) or purified recombinant PV protein (5  $\mu$ M; **Figs. S6, S7**),  
500 in addition to Fluo-5F (250  $\mu$ M) in the pipette solution. As expected, we observed a significant  
501 increase in the decay time constant and a decrease in the amplitude of the calcium transients.

502

503 In conclusion, our study broadens the understanding of Shank3 deficiency beyond the previously  
504 reported HCN channelopathy to include abnormalities in calcium signaling (**Fig. 7**). We discovered  
505 reduced PV expression and the corresponding decreases in calcium buffering capacity in Shank3<sup>-/-</sup>  
506 /- VTA DA neurons. Abnormal calcium buffering capacity has been implicated in several  
507 neuropsychiatric disorders, and here our study of Shank3<sup>-/-</sup> VTA DA neurons provides crucial  
508 evidence for this connection. Clinical treatments targeting calcium buffer capacity may represent a  
509 novel therapeutic avenue not only for ASD but also for other neuropsychological disorders.

510

511

512

513

514

515

516 **References**

- 517 Bariselli S, Contestabile A, Tzanoulinou S, Musardo S, Bellone C (2018) SHANK3 Downregulation  
518 in the Ventral Tegmental Area Accelerates the Extinction of Contextual Associations  
519 Induced by Juvenile Non-familiar Conspecific Interaction. *Front Mol Neurosci* 11:360.
- 520 Bariselli S, Tzanoulinou S, Glangetas C, Prevost-Solie C, Pucci L, Viguie J, Bezzi P, O'Connor EC,  
521 Georges F, Luscher C, Bellone C (2016) SHANK3 controls maturation of social reward  
522 circuits in the VTA. *Nat Neurosci* 19:926-934.
- 523 Brinley FJ, Jr. (1978) Calcium buffering in squid axons. *Annu Rev Biophys Bioeng* 7:363-392.
- 524 Clapham DE (2007) Calcium signaling. *Cell* 131:1047-1058.
- 525 Cohen JY, Haesler S, Vong L, Lowell BB, Uchida N (2012) Neuron-type-specific signals for reward  
526 and punishment in the ventral tegmental area. *Nature* 482:85-88.
- 527 Collin T, Chat M, Lucas MG, Moreno H, Racay P, Schwaller B, Marty A, Llano I (2005)  
528 Developmental changes in parvalbumin regulate presynaptic Ca<sup>2+</sup> signaling. *J Neurosci*  
529 25:96-107.
- 530 Combe CL, Gasparini S (2021) I(h) from synapses to networks: HCN channel functions and  
531 modulation in neurons. *Prog Biophys Mol Biol* 166:119-132.
- 532 Contractor A, Ethell IM, Portera-Cailliau C (2021) Cortical interneurons in autism. *Nat Neurosci*  
533 24:1648-1659.
- 534 Delling JP, Boeckers TM (2021) Comparison of SHANK3 deficiency in animal models: phenotypes,  
535 treatment strategies, and translational implications. *J Neurodev Disord* 13:55.
- 536 Delvendahl I, Jablonski L, Baade C, Matveev V, Neher E, Hallermann S (2015) Reduced endogenous  
537 Ca<sup>2+</sup> buffering speeds active zone Ca<sup>2+</sup> signaling. *Proc Natl Acad Sci U S A* 112:E3075-  
538 3084.
- 539 Drapeau E, Riad M, Kajiwara Y, Buxbaum JD (2018) Behavioral Phenotyping of an Improved Mouse  
540 Model of Phelan-McDermid Syndrome with a Complete Deletion of the Shank3 Gene.  
541 *eNeuro* 5.
- 542 Durand CM et al. (2007) Mutations in the gene encoding the synaptic scaffolding protein SHANK3  
543 are associated with autism spectrum disorders. *Nat Genet* 39:25-27.
- 544 Eisner D, Neher E, Taschenberger H, Smith G (2023) Physiology of intracellular calcium buffering.  
545 *Physiol Rev* 103:2767-2845.

546 Enomoto M, Nishikawa T, Siddiqui N, Chung S, Ikura M, Stathopoulos PB (2017) From Stores to  
547 Sinks: Structural Mechanisms of Cytosolic Calcium Regulation. *Adv Exp Med Biol* 981:215-  
548 251.

549 Evans RC, Blackwell KT (2015) Calcium: amplitude, duration, or location? *Biol Bull* 228:75-83.

550 Fakler B, Adelman JP (2008) Control of K(Ca) channels by calcium nano/microdomains. *Neuron*  
551 59:873-881.

552 Filice F, Janickova L, Henzi T, Bilella A, Schwaller B (2020) The Parvalbumin Hypothesis of Autism  
553 Spectrum Disorder. *Front Cell Neurosci* 14:577525.

554 Franconville R, Revet G, Astorga G, Schwaller B, Llano I (2011) Somatic calcium level reports  
555 integrated spiking activity of cerebellar interneurons in vitro and in vivo. *J Neurophysiol*  
556 106:1793-1805.

557 Halbedl S, Schoen M, Feiler MS, Boeckers TM, Schmeisser MJ (2016a) Shank3 is localized in axons  
558 and presynaptic specializations of developing hippocampal neurons and involved in the  
559 modulation of NMDA receptor levels at axon terminals. *J Neurochem* 137:26-32.

560 Halbedl S, Schoen M, Feiler MS, Boeckers TM, Schmeisser MJ (2016b) Shank3 is localized in axons  
561 and presynaptic specializations of developing hippocampal neurons and involved in the  
562 modulation of NMDA receptor levels at axon terminals. *J Neurochem* 137:26-32.

563 Han QJ, Kim YH, Wang XM, Liu D, Zhang ZJ, Bey AL, Lay M, Chang W, Berta T, Zhang Y, Jiang YH, Ji  
564 RR (2016) SHANK3 Deficiency Impairs Heat Hyperalgesia and TRPV1 Signaling in Primary  
565 Sensory Neurons. *Neuron* 92:1279-1293.

566 Helmchen F, Tank DW (2015) A single-compartment model of calcium dynamics in nerve terminals  
567 and dendrites. *Cold Spring Harb Protoc* 2015:155-167.

568 Hou P, Xiao F, Liu H, Yuchi M, Zhang G, Wu Y, Wang W, Zeng W, Ding M, Cui J, Wu Z, Wang LY,  
569 Ding J (2016) Extrapolating microdomain Ca(2+) dynamics using BK channels as a Ca(2+)  
570 sensor. *Sci Rep* 6:17343.

571 Hu H, Gan J, Jonas P (2014) Interneurons. Fast-spiking, parvalbumin(+) GABAergic interneurons:  
572 from cellular design to microcircuit function. *Science* 345:1255263.

573 Janickova L, Rechberger KF, Wey L, Schwaller B (2020) Absence of parvalbumin increases  
574 mitochondria volume and branching of dendrites in inhibitory Pvalb neurons in vivo: a  
575 point of convergence of autism spectrum disorder (ASD) risk gene phenotypes. *Mol*  
576 *Autism* 11:47.

577 Jedrzejewska-Szmek J, Dorman DB, Blackwell KT (2023) Making time and space for calcium control  
578 of neuron activity. *Curr Opin Neurobiol* 83:102804.

579 Jung S, Chung Y, Lee Y, Lee Y, Cho JW, Shin EJ, Kim HC, Oh YJ (2019) Buffering of cytosolic calcium  
580 plays a neuroprotective role by preserving the autophagy-lysosome pathway during  
581 MPP(+)-induced neuronal death. *Cell Death Discov* 5:130.

582 Kumar P, Goettemoeller AM, Espinosa-Garcia C, Tobin BR, Tfaily A, Nelson RS, Natu A, Dammer  
583 EB, Santiago JV, Malepati S, Cheng L, Xiao H, Duong DD, Seyfried NT, Wood LB, Rowan  
584 MJM, Rangaraju S (2024) Native-state proteomics of Parvalbumin interneurons identifies  
585 unique molecular signatures and vulnerabilities to early Alzheimer's pathology. *Nat*  
586 *Commun* 15:2823.

587 Leblond CS et al. (2014) Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: a  
588 gradient of severity in cognitive impairments. *PLoS Genet* 10:e1004580.

589 Leybaert L, Sanderson MJ (2012) INTERCELLULAR Ca  
590 WAVES: MECHANISMS AND FUNCTION. *Physiol Rev* 92:1359-1392.

591 Ma X, Miraucourt LS, Qiu H, Sharif-Naeini R, Khadra A (2023) Modulation of SK Channels via  
592 Calcium Buffering Tunes Intrinsic Excitability of Parvalbumin Interneurons in Neuropathic  
593 Pain: A Computational and Experimental Investigation. *J Neurosci* 43:5608-5622.

594 Maravall M, Mainen ZF, Sabatini BL, Svoboda K (2000) Estimating intracellular calcium  
595 concentrations and buffering without wavelength ratioing. *Biophys J* 78:2655-2667.

596 Matthews EA, Dietrich D (2015) Buffer mobility and the regulation of neuronal calcium domains.  
597 *Front Cell Neurosci* 9:48.

598 Morales M, Margolis EB (2017) Ventral tegmental area: cellular heterogeneity, connectivity and  
599 behaviour. *Nat Rev Neurosci* 18:73-85.

600 Nanou E, Catterall WA (2018) Calcium Channels, Synaptic Plasticity, and Neuropsychiatric Disease.  
601 *Neuron* 98:466-481.

602 Pchitskaya E, Popugaeva E, Bezprozvanny I (2018) Calcium signaling and molecular mechanisms  
603 underlying neurodegenerative diseases. *Cell Calcium* 70:87-94.

604 Peca J, Feliciano C, Ting JT, Wang W, Wells MF, Venkatraman TN, Lascola CD, Fu Z, Feng G (2011)  
605 Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. *Nature*  
606 472:437-442.

607 Ruden JB, Dugan LL, Konradi C (2021) Parvalbumin interneuron vulnerability and brain disorders.  
608 *Neuropsychopharmacology* 46:279-287.

609 Santoro B, Shah MM (2020) Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels as  
610 Drug Targets for Neurological Disorders. *Annu Rev Pharmacol Toxicol* 60:109-131.

611 Schultz W, Dayan P, Montague PR (1997) A neural substrate of prediction and reward. *Science*  
612 275:1593-1599.

613 Schwaller B (2020) Cytosolic Ca(2+) Buffers Are Inherently Ca(2+) Signal Modulators. *Cold Spring*  
614 *Harb Perspect Biol* 12.

615 Tang X, Jaenisch R, Sur M (2021) The role of GABAergic signalling in neurodevelopmental  
616 disorders. *Nat Rev Neurosci* 22:290-307.

617 Wang X, Xu Q, Bey AL, Lee Y, Jiang YH (2014) Transcriptional and functional complexity of Shank3  
618 provides a molecular framework to understand the phenotypic heterogeneity of SHANK3  
619 causing autism and Shank3 mutant mice. *Mol Autism* 5:30.

620 Wang X et al. (2016) Altered mGluR5-Homer scaffolds and corticostriatal connectivity in a Shank3  
621 complete knockout model of autism. *Nat Commun* 7:11459.

622 Yi F, Danko T, Botelho SC, Patzke C, Pak C, Wernig M, Sudhof TC (2016) Autism-associated SHANK3  
623 haploinsufficiency causes Ih channelopathy in human neurons. *Science* 352:aaf2669.

624 Zhou Z, Neher E (1993) Mobile and immobile calcium buffers in bovine adrenal chromaffin cells. *J*  
625 *Physiol* 469:245-273.

626 Zhu M, Idikuda VK, Wang J, Wei F, Kumar V, Shah N, Waite CB, Liu Q, Zhou L (2018) Shank3-  
627 deficient thalamocortical neurons show HCN channelopathy and alterations in intrinsic  
628 electrical properties. *J Physiol* 596:1259-1276.

629  
630

631 **Figures and Tables**

632

633 **Figure 1. Abnormal action potential (AP) firing and resting membrane potential (RMP) in**  
634 **Shank3<sup>-/-</sup> VTA DA neurons.**

635 **A.** Left, distribution of DA neurons in the whole brain. Red, immunostaining of tyrosine hydroxylase  
636 (TH) as a marker for DA neurons; blue, DAPI as a marker for cell nuclei. Scale bar, 1 mm.  
637 Right, three types of VTA DA neurons filled with AF594 as a tracer for cell morphology. Scale  
638 bar, 20  $\mu$ m.

639 **B.** AP firing of VTA DA neurons from WT and Shank3<sup>-/-</sup> mice evoked by current injection (150  
640 pA).

641 **C.** Averaged results show reduced AP firing in Shank3<sup>-/-</sup> neurons. Animals used: 4 (WT), 3  
642 (Shank3<sup>-/-</sup>). Neurons recorded, 12 (WT), 14 (Shank3<sup>-/-</sup>). P-value: 50 pA, 0.002; 75 pA, 0.010.

643 **D.** AP half-width vs. current injection amplitude. Black, WT (n=14); Red, Shank3<sup>-/-</sup> (n=24).  
644 Neurons recorded, 12 (WT), 9 (Shank3<sup>-/-</sup>). P-value: 200 pA, 0.024.

645 **E.** AP amplitude vs. current injection amplitude. Black, WT (n=14); Red, Shank3<sup>-/-</sup> (n=24).  
646 Neurons recorded, 13 (WT), 14 (Shank3<sup>-/-</sup>). P-value: 200 pA, 0.008.

647 **F.** Averaged RMP and Rin of WT and Shank3<sup>-/-</sup> DA neurons. Animals used: 7 (WT), 10 (Shank3<sup>-/-</sup>).  
648 Neurons recorded, 14 (WT), 24 (Shank3<sup>-/-</sup>). P-value: RMP, 0.020; Rin, 0.901.

649

650 **Figure 2. Abnormal calcium transients in the soma of Shank3<sup>-/-</sup> VTA DA neurons.**

651 **A.** Two-photon imaging of somatic calcium transients in WT (left) and Shank3<sup>-/-</sup> (right) DA  
652 neurons. 4 current pulse injections, with the setting of 2 nA / 2 msec / 2 Hz, were used to elicit  
653 AP firing. Top, current pulse. Bottom, membrane potential.

654 **B.** Calcium transients recorded with 200 mM Fluo-4 ( $K_D$ , 345 nM) added to the pipette solution.

655 **C.** Overlay of WT (black) and Shank3<sup>-/-</sup> (red) calcium transients recorded with 200 mM Fluo-4  
656 loaded through the whole-cell recording electrode.

657 **D.** Overlay of WT (black) and Shank3<sup>-/-</sup> (red) calcium transients recorded with 250 mM Fluo-5F.

658 **E.** Averaged results of the decay time constant (left) and the amplitude of the four calcium peaks  
659 (right). Measured with Fluo-4 in the pipette solution. Animals used: 2 (WT), 2 (Shank3<sup>-/-</sup>).  
660 Neurons recorded, 7 (WT), 7 (Shank3<sup>-/-</sup>). P-value: tau, 0.013; DF/F (peaks 1-4), 0.057, 0.072,  
661 0.143, 0.138.

662 **F.** Averaged results of the decay time constant (left) and the amplitude of the four calcium peaks  
663 (right). Measured with Fluo-5F in the pipette solution. Animals used: 5 (WT), 5 (Shank3<sup>-/-</sup>).  
664 Neurons recorded, 7 (WT), 9 (Shank3<sup>-/-</sup>). P-value: tau, 0.012; DF/F (peaks 1-4), 0.179, 0.336,  
665 0.296, 0.648.

666

667 **Figure 3. Altered calcium transient profile in Shank3<sup>-/-</sup> VTA DA neuron dendric shaft.**  
668 **A.** Left, two-photon fluorescence image of a VTA DA neuron filled with AF594 (red channel) and  
669 Fluo-4. Right, calcium transients evoked by a train of 4 current pulses (2 nA, 2 msec, 2 Hz).  
670 Overlay of calcium transient traces recorded from dendrites (50, 100, 150 mm from soma; top  
671 to bottom) from WT and Shank3<sup>-/-</sup> DA neurons (WT, n=7; Shank3<sup>-/-</sup>, n=7; right).  
672 **B.** Averaged results of the decay time constant of dendritic calcium transients as a function of  
673 distance from the soma. Animals used: 2 (WT), 2 (Shank3<sup>-/-</sup>). Neurons recorded, 10 (WT), 15  
674 (Shank3<sup>-/-</sup>). P-value: tau (50-100-150), 0.003, 0.014, 0.001.  
675 **C.** Statistics of 4 peaks of calcium transients recorded from three dendritic locations. P-value: (50  
676 – 100 – 150 mm) peak 1, 0.0002 0.0004 0.008; peak 2, 0.005 0.012 0.011; peak 3, 0.002  
677 0.018 0.046; peak 4 0.031 0.019 0.009.  
678 **D.** Left, two-photon fluorescence image of a VTA DA neuron filled with AF594 (red channel) and  
679 Fluo-5F. Right, calcium transients evoked by a train of 4 current pulses (2 nA, 2 msec, 2 Hz).  
680 Overlay of calcium transient traces recorded from dendrites (50, 100, 150 mm from soma; top  
681 to bottom) from WT and Shank3<sup>-/-</sup> DA neurons (WT, n=8; Shank3<sup>-/-</sup>, n=10; right).  
682 **E.** Averaged results of the decay time constant of dendritic calcium transients. Animals used:  
683 4(WT), 5 (Shank3<sup>-/-</sup>). Neurons recorded, 11 (WT), 10 (Shank3<sup>-/-</sup>). P-value: tau (50-100-150),  
684 0.013, 0.037, 0.030.  
685 **F.** Statistics of 4 peaks of calcium transients recorded from three dendritic locations. P-value: (50  
686 – 100 – 150 mm) peak 1, 0.015 0.018 0.050; peak 2, 0.048 0.147 0.522; peak 3, 0.058 0.077  
687 0.311; peak 4 0.277 0.241 0.993.  
688

689 **Figure 4. Mass-spectrometry revealed a reduced level of PV protein in Shank3<sup>-/-</sup> VTA area.**  
690 **A.** Schematic illustration of the mass spectrometry analysis of isolated brain tissues from WT  
691 (n=3) and Shank3<sup>-/-</sup> (n=3) VTA regions. A total of 4882 proteins were identified, with 132  
692 proteins showing differential expression between WT and SHANK3<sup>-/-</sup> samples (P < 0.05).  
693 **B.** Volcano plot of mass spectrometry results showing proteins with significantly upregulated  
694 levels (right, red, 86) and down-regulated levels (left, green, 46). The X- and Y-axis represent  
695 the fold change in log<sub>2</sub> and the logarithm of the P-value, respectively.  
696 **C.** Gene-ontology (GO) analysis results are categorized into biological processes (BP, green),  
697 cellular components (CC, orange), and molecular functions (MF, blue). The X-axis indicates  
698 the number of proteins in each significantly enriched term (p-adjust < 0.05).  
699 **D.** Statistics of KEGG enrichment of WT and Shank3<sup>-/-</sup> results, including 10 significantly enriched  
700 pathways (Y-axis, p-adjust < 0.05) and 21 genes (X-axis). Bubble color represents the log<sub>2</sub> fold  
701 change (FC) value of each gene, with orange denoting up-regulated and green indicating  
702 down-regulated expression in the Shank3<sup>-/-</sup> group relative to WT.

- 703 **E.** Immunostaining of PV (green) and TH (red) in coronal slices of WT and Shank3<sup>-/-</sup> brains.  
704 Collected by 10X lens and assembled by Image Mosaicing program. Scale bar, 1 mm.  
705 **F.** PV expression in the VTA area of WT and Shank3<sup>-/-</sup> mice. Collected by 60X oil lens. Scale  
706 bar, 50  $\mu$ m.  
707 **G.** Zoomed-in view over the box shown in G. Notice that the much weaker green signal (PV) in  
708 Shank3<sup>-/-</sup> neurons makes the composite image appear red, in contrast to the yellowish image  
709 of WT neurons.  
710 **H.** Statistics of immunostaining results. Animals used: 3 (WT), 4 (Shank3<sup>-/-</sup>). Brain slices imaged,  
711 10 (WT), 12 (Shank3<sup>-/-</sup>). P-value, neuron number 0.212, TH 0.042, PV, <0.0001.

712

713 **Figure 5. Quantification of somatic calcium buffer capacity in WT and Shank3<sup>-/-</sup> VTA DA**  
714 **neurons by Fluo-4 two-photon imaging.**

- 715 **A.** Representative IR-DIC image of a VTA DA neuron and the corresponding two-photon images  
716 of the soma (with recording electrode) filled with AF594 (10  $\mu$ M) and Fluo-4 (200  $\mu$ M). Somatic  
717 calcium transients elicited by 4 current injections (2 msec, 2 Hz, 2 nA). Top, current injections;  
718 bottom, membrane potential signal.  
719 **B.** Normalized calcium transients recorded at two time points.  
720 **C.** Fluorescence intensity (black) and  $K_B$  (red) as a function of time after seal rupture and the  
721 formation of whole-cell recording configuration.  
722 **D.** Time constant of the decay of calcium transients as a function of recording time.  
723 **E.** Cross plot of time constant and  $K_B$  and the linear regression fit.  
724 **F.** Statistics of the  $K_E$  values of WT (black) and Shank3<sup>-/-</sup> (red) neurons. Animals used: 3 (WT), 5  
725 (Shank3<sup>-/-</sup>). Neurons recorded, 7 (WT), 7 (Shank3<sup>-/-</sup>). P-value: 0.033.  
726 **G.** Equations for the calculation of  $K_B$  and t- $K_B$ - $K_E$  relationship.

727

728 **Figure 6. Quantification of somatic calcium buffer capacity in WT and Shank3<sup>-/-</sup> VTA DA**  
729 **neurons by Fura-8 ratiometric calcium imaging.**

730

- 731 **A.** Configuration of the home-built imaging system for ratiometric calcium measurements.  
732 **B.** Raw images of a WT VTA DA neuron filled with 50  $\mu$ M Fura-8 and recorded at three different  
733 time points as indicated by \* in the figure below. Top, 365 nm excitation; bottom, 410  
734 excitation. Scale bar, 20  $\mu$ m.  
735 **C.** DA neurons stimulated by a train of 16 current injections (2 nA, 2 msec, 50 Hz). Top, current  
736 injections; bottom, membrane potential.  
737 **D.** Fluorescence intensities recorded with the excitation of 365 nm (top) and 410 nm (bottom).  
738 Left, WT; right, Shank3<sup>-/-</sup>.

- 739 **E.** Traces of  $F_{365}/F_{410}$  based on recordings shown in L.
- 740 **F.** Calcium transients ( $F_{365}/F_{410}$ ) recorded from a WT DA neuron filled with 50 mM Fura-8
- 741 recorded at 4 min (top) and 16 min (bottom) after membrane break-in.
- 742 **G.** Fluorescence intensity and  $K_B$  as a function of time after membrane break-in.
- 743 **H.** Statistics of measured endogenous calcium buffer power ( $K_E$ ) of WT (n=15) and Shank3-/-
- 744 (n=15) VTA DA neurons. Animals used: 3 (WT), 3 (Shank3-/-). Neurons recorded, 10 (WT),
- 745 10 (Shank3-/-). P-value: <0.0001.


746


747 **Figure 7. Schematic drawing shows Shank3 as a key structural protein in coordinating the**


748 **protein surface expression and localization of numerous channels and receptors and the**

749 **cytosolic expression of the PV protein.**

750










**E** WT (PV+TH+DAPI)

Shank3<sup>-/-</sup> (PV+TH+DAPI)



**F**


PV

TH

PV + TH + DAPI

WT


Shank3<sup>-/-</sup>



**G**

WT

Shank3<sup>-/-</sup>



**H**







Fig. 5







## 1 **Supporting Information:**

2

### 3 **Fig. S1. Pharmacological perturbations of somatic calcium transients in WT VTA DA** 4 **neurons.**

5 **A.** Somatic calcium transients (bottom) evoked by four short current injections (2 nA, 2 msec, 50  
6 Hz, top), recorded from a WT VTA DA neuron. The corresponding membrane potential is  
7 shown in the middle.

8 **B.** DHPG (50 mM, added in ACSF) prolonged the decay of the calcium transients shown in A.

9 **C.** Statistical results of the effect of DHPG on the decay time constant of calcium transients of  
10 WT (n=6, black, P-value, 0.017) and Shank3<sup>-/-</sup> (n=7, orange, P-value, <0.0001) VTA DA  
11 neurons.

12 **D.** Statistical results of the effect of caffeine (5 mM, added in ACSF) on the decay time constant  
13 of calcium transients of WT (n=8, black, P-value, <0.0001) and Shank3<sup>-/-</sup> (n=9, blue, P-value,  
14 <0.0001) VTA DA neurons.

15 **E.** Statistical results of the effect of ryanodine (75 mM, added in the pipette solution) on the decay  
16 time constant of calcium transients of WT (n=8, black, P-value, 0.271) and Shank3<sup>-/-</sup> (n=8,  
17 green, P-value, 0.701) VTA DA neurons.

18 **F.** Statistical results of the effect of isradipine (5 mM, added in ACSF) on the decay time constant  
19 of calcium transients of WT (n=9, black, P-value, 0.004) and Shank3<sup>-/-</sup> (n=9, red, P-value,  
20 0.0014) VTA DA neurons. Type or paste legend here. Paste figure above the legend.

21

### 22 **Fig. S2. Shank3 associated genes via PV identified by mass-spectrometry and protein-** 23 **protein interaction (PPI).**

24 Using the STRING database, PPI analysis of significantly differentially expressed genes reveals  
25 *Shank3* is associated with *Cbln1*, *Titin*, *TPM2*, *FLNC*, *FLNB*, and other genes via PV. Notably,  
26 *Cbln1* has been shown to rapidly induce synaptogenesis, while *TPM2* inhibits cell migration.  
27 Similarly, the significant downregulation of *SLIT2* may lead to increased cell migration.  
28 Downregulation of *FLNB* may result in reduced cell migration mediated by cell signaling  
29 perception, while significant downregulation of the *DYRK1A* gene and significant upregulation  
30 of the *DSCAM* gene both resulted in increased neuronal generation and maturation.  
31 Collectively, these results suggest that Shank3 deficiency may drive a cellular phenotype  
32 characterized by increased migration and impaired signaling centered on PV-associated  
33 pathways, potentially accompanied by impaired neuronal development and maturation.

34

### 35 **Fig. S3. Reduced PV expression in Shank3<sup>-/-</sup> and Shank3<sup>+/-</sup> VTA DA neurons.**

- 36 **A.** Immunostaining of PV (green), TH (red), and DAPI (blue) in coronal slices of WT and  
37 Shank3<sup>-/-</sup> mouse brain slices.
- 38 **B.** Statistics of immunostaining results. Total number of analyzed brain slices: 8 (WT), 9  
39 (Shank3<sup>-/-</sup>). P-value: TH<sup>+</sup> neuron number, 0.197; TH fluorescence, 0.218; PV  
40 fluorescence, <0.0001.
- 41 **C.** Immunostaining of PV (green), TH (red), and DAPI (blue) in WT and Shank3<sup>+/-</sup>  
42 mouse brain slices. Zoomed view of the regions indicated by dashed boxes are  
43 shown below.
- 44 **D.** Pixels with TH signal (red channel) higher than 50 are selected from the whole  
45 pictures shown in C, top. The corresponding PV signal intensities (green channel) of  
46 these pixels are pooled together and shown in histogram plots.
- 47 **E.** Left, histogram plots of 4 WT and 4 Shank3<sup>+/-</sup> brain slices support a significant  
48 decrease in PV expression in Shank3<sup>+/-</sup> VTA DA neurons. Right, statistical results of  
49 the PV signal intensities at peak distribution. Number of brain slices: 4; P-value,  
50 0.0016.
- 51 **F.** *In-situ* hybridization (ISH) data of PV (left) and the corresponding reference brain  
52 atlas (right), obtained from websites of Allen Institute. A zoomed view of the VTA  
53 region is shown below.

54  
55 **Fig. S4. Immunostaining of PV in the cortex.**

- 56 **A.** Immunostaining of PV (green) in coronal brain slices of WT (left) and Shank3<sup>-/-</sup> (right) mice.  
57 Scale bar, 100  $\mu$ m.
- 58 **B.** Statistical results. Number of brain slices used in PV fluorescence analysis: WT, 9; Shank3<sup>-/-</sup>  
59 , 9. P-value: neuron number, 0.100; PV fluorescence, 0.001.

60  
61 **Fig. S5. Effects of adding additional EGTA in pipette solution on calcium transients recorded**  
62 **from VTA DA neurons.**

- 63 **A.** Somatic calcium transients (bottom) elicited by four short current injections (2 nA, 2 msec, 2  
64 Hz, top), recording from a Shank3<sup>-/-</sup> VTA DA neuron. The corresponding membrane potential  
65 is shown in the middle. Changes in neuronal calcium signaling induced by action potentials  
66 are shown in the bottom.
- 67 **B.** EGTA (350  $\mu$ M, added in pipette solution) prolonged the decay of the calcium transients  
68 shown in A.
- 69 **C.** Image of a VTA DA neuron filled with AF594 and calcium indicator Fluo-5F.

- 70 **D.** The time constant of the decay of calcium transients recorded from the soma and three  
71 locations along the dendritic shaft. Black, control (Shank3<sup>-/-</sup>, n=8); red, Shank3<sup>-/-</sup> neurons  
72 filled with EGTA (n=8).
- 73 **E.** Amplitudes of 4 consecutive peaks of calcium signal recorded from the soma.
- 74 **F.** Amplitudes of 4 consecutive peaks of calcium signal recorded from three locations along the  
75 dendritic shaft (from left to right, 50, 100, and 150 mm from the soma).

76

77 **Fig. S6. SDS-PAGE gel of protein samples collected during the expression and purification**  
78 **of recombinant PV protein.**

79

80 **Fig. S7. Effects of adding purified PV protein in pipette solution on calcium transients**  
81 **recorded from VTA DA neurons.**

- 82 **A.** Somatic calcium transients (bottom) elicited by four short current injections (2 nA, 2 msec, 2  
83 Hz, top), recorded from a Shank3<sup>-/-</sup> VTA DA neuron. The corresponding membrane potential  
84 is shown in the middle.
- 85 **B.** PV protein (5 mM, added in pipette solution) prolonged the decay of the calcium transients  
86 shown in A.
- 87 **C.** Image of a VTA DA neuron filled with AF594 and calcium indicator Fluo-5F.
- 88 **D.** The time constant of the decay of calcium transients recorded from the soma and three  
89 locations along the dendritic shaft. Black, control (Shank3<sup>-/-</sup>, n=8); red, Shank3<sup>-/-</sup> neurons  
90 filled with recombinant PV protein (n=9).
- 91 **E.** Amplitudes of 4 consecutive peaks of calcium transients recorded from the soma.
- 92 **F.** Amplitudes of 4 consecutive peaks of calcium transients recorded from three locations along  
93 the dendritic shaft (from left to right, 50, 100, and 150 mm from the soma).

94

95

96

97

Fig. S1






Fig. S3







Fig. S3

C

WT (PV / TH)

Shank3+/- (PV / TH)



100  $\mu$ m





Fig. S3






Fig. S3

**F** Parvalbumin *in situ* hybridization image data (Allen Institute; from <https://atlas.brain-map.org/>)






Fig. S4






Fig. S6

